Truway Health, Inc. , View 34, 401 E 34th Street, S11P, New York, NY 10016
New York, 10016, United States
NCT Number: NCT07217730
The PHX-AFK-US Protocol is a coalition-backed regulatory scaffold designed to restore healthcare integrity across U.S. facilities. It targets fraud, kickback schemes, and supply chain opacity through validator governance, smart contract enforcement, and public transparency. Anchored by notarized affidavits, NFT fiscal instruments, and dashboard oversight, this protocol empowers whistleblowers, mobilizes validators, and escalates complaints to federal and state regulators. It integrates secure audit trails, DAO voting logic, and asset freeze triggers to ensure accountability, reform, and systemic trust.
Interested in participating?
Request InfoAll sexes
Observational
New York, 10016, United States
The PHX-AFK-US Protocol is a coalition-backed regulatory scaffold designed to restore healthcare integrity across U.S. facilities. It targets fraud, kickback schemes, and supply chain opacity through validator governance, smart contract enforcement, and public transparency. Anchored by notarized affidavits, NFT fiscal instruments, and dashboard oversight, this protocol empowers whistleblowers, mobilizes validators, and escalates complaints to federal and state regulators. It integrates secure audit trails, DAO voting logic, and asset freeze triggers to ensure accountability, reform, and systemic trust.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Facility has documented billing, compliance, or procurement irregularities.
Facility participates in coalition validator onboarding and SHA-256 protocol enrollment.
Facility provides access to billing, procurement, and whistleblower-anchored datasets for auditing.
Exclusion criteria
Facility refuses validator onboarding or coalition integration.
Facility lacks traceable procurement or compliance records.
Facility has no whistleblower declaration or validation artifact.
Facility operates outside U.S. jurisdiction or coalition-recognized governance zones.
This intervention deploys a validator-governed framework to monitor, escalate, and reform healthcare facilities exhibiting fraud, kickback schemes, and supply chain vulnerabilities. It integrates notarized affidavits, smart contract enforcement, NFT fiscal declarations, and DAO voting logic to trigger sanctions, regulatory complaints, and operational restructuring. Facilities are observed prospectively, with all actions logged to a public dashboard and anchored via SHA-256 hash notarization. No biospecimens are retained; all data is legal, technical, and governance-based.
Other names: PHX-AFK-US Protocol
The Coalition-Grade Validator Dashboard Module (CVDM-1) is a secure, web-based device deployed across enrolled healthcare facilities to enable real-time validator oversight, whistleblower affidavit intake, and smart contract enforcement. It integrates QR-linked audit trails, NFT fiscal declarations, and DAO voting logic. The device anchors all inputs via SHA-256 hash notarization and transmits reform metrics to coalition dashboards. CVDM-1 supports public transparency, regulatory escalation, and validator governance across the PHX-AFK-US Protocol. It does not collect biospecimens and operates solely within legal, technical, and governance domains.
Other names: PHX-AFK-US Governance Terminal
The Coalition-Flagged Pharmaceutical Audit Trigger (CFPAT-1) is a governance-based drug intervention targeting facilities with suspected fraud, kickback schemes, or supply chain irregularities involving pharmaceuticals. While not a therapeutic agent, CFPAT-1 functions as a regulatory scaffold that flags drug procurement, formulary manipulation, and referral-linked prescribing patterns. It integrates validator ballots, smart contract logic, and SHA-256 hash anchors to escalate complaints to CMS, DOJ, and state boards. All flagged drugs are traced via QR-linked audit trails and NFT fiscal declarations. No biospecimens are retained; the intervention operates within legal, technical, and governance domains.
Other names: CFPAT-1
Time frame: Baseline to 12 Months Post-Validator Onboarding
Description:
This outcome measures the change in frequency and severity of fraudulent billing practices-including upcoding, phantom billing, and referral-based kickback schemes-across facilities enrolled in the SHA-256 Trial Protocols.
Facilities are assessed using the Unified Impact Index derived from:
Historical billing anomalies
Validator audit results
Whistleblower declarations
SHA-256 hash-anchored incident reports
Facilities are ranked and monitored for reform compliance, ethical standards, and onboarding validation. All scoring logic is notarized and displayed via coalition dashboards.
Time Frame: Baseline to 12 Months Post-Validator Onboarding.
Time frame: Baseline to 12 Months Post-Validator Onboarding
This outcome measures change in traceability and regulatory compliance for pharmaceuticals, medical devices, and non-pharmaceutical supplies. Facilities are evaluated using:
Validator Traceability Score (VTS) composite metrics
NFT tagging for supply-chain nodes
Blockchain-based audit trails
Comparative analysis dashboards identifying gaps and escalation pathways for non-compliant entities
Truway Health, Inc.
Industry
§ PHX-AFK-US: Public Health Exchange Protocol for Anti-Fraud, Kickback Prevention & Secure Chain Integrity in U.S. Healthcare Facilities
Acronym: PHX-AFK-US
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07400796
Adherence, Anemia
Phnom Penh, Cambodia
View Trial Details